Kainos Laboratories

Kainos Laboratories EBITDA per Share

Delisted

The EBITDA per Share of Kainos Laboratories (4556.T) as of Oct 30, 2026 is 209.50 JPY. In the previous year, EBITDA per Share was 223.49 JPY — a change of -6.26% (lower).

EBITDA per Share

209.50JPY

YoY

-6.26%

Last updated:

EBITDA per Share of Kainos Laboratories is 2025 209.50 JPY. EBITDA per Share of Kainos Laboratories was 2024 223.49 JPY. It decreases by -6.26% lower compared to the previous year.

The Kainos Laboratories EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
119.93 JPY
Jan 1, 2019
159.77 JPY
Jan 1, 2020
161.99 JPY
Jan 1, 2021
167.52 JPY
Jan 1, 2022
198.29 JPY
Jan 1, 2023
211.65 JPY
Jan 1, 2024
223.49 JPY
Jan 1, 2025
209.50 JPY
The Kainos Laboratories EBITDA per Share history
YEAREBITDA per ShareYoY
209.50JPY-6.26%
223.49JPY+5.60%
211.65JPY+6.74%
198.29JPY+18.36%
167.52JPY+3.42%
161.99JPY+1.39%
159.77JPY+33.22%
119.93JPY-4.66%
125.79JPY+7.78%
116.71JPY+10.52%
105.60JPY+24.08%
85.11JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kainos Laboratories Stock analysis

What does Kainos Laboratories do? Kainos Laboratories Inc develops and manufactures pharmaceuticals, diagnostic reagents, and related chemical products for distribution and import/export. The company sells its products to healthcare providers, hospitals, and medical institutions within Japan and internationally. Its core offerings include prescription medications, diagnostic tools, and chemical compounds used in medical research and treatment. The business model relies on direct sales to medical facilities and global trade of its pharmaceutical and diagnostic solutions. Kainos Laboratories Inc focuses on the Japanese market with its headquarters in Bunkyo-Ku, Tokyo-To, while also engaging in international import/export activities. The company's revenue streams come from the sale of pharmaceuticals, diagnostic reagents, and chemical products to healthcare professionals and institutions. Its product portfolio targets medical practitioners and research organizations requiring specialized diagnostic and therapeutic solutions. The company operates with 144 full-time employees dedicated to the development, manufacturing, and distribution of its products. Kainos Laboratories Inc generates income through the commercialization of its pharmaceuticals and diagnostic reagents, serving both domestic and global clients in the healthcare sector. Sales are driven by demand for medical treatments and diagnostic tools in clinical and research settings. Kainos Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kainos Laboratories stock

EBITDA per Share of Kainos Laboratories is 209.50 JPY in 2025.

EBITDA per Share of Kainos Laboratories changed from 223.49 JPY to 209.50 JPY, representing a -6.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Kainos Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Kainos Laboratories

All Key Metrics — Kainos Laboratories